GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Clinical trials for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection aims to slow vision loss in Age-Related eye disease
Disease control Recruiting nowThis study is testing whether a new medication called ADX-038, given as an injection under the skin, can slow the progression of geographic atrophy—a form of age-related macular degeneration that causes permanent vision loss. About 240 participants with this condition will receiv…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 04, 2026 08:51 UTC
-
One-Shot gene injection aims to halt blinding eye disease
Disease control Recruiting nowThis early-stage study is testing a new, one-time gene therapy called VV-14295 for people with geographic atrophy (GA), an advanced form of age-related macular degeneration that causes progressive vision loss. Researchers will inject the therapy into the eye to see if it is safe …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Kriya Therapeutics, Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug combo aims to halt blinding eye disease
Disease control Recruiting nowThis study is testing whether adding a new investigational drug called APL-3007 to an existing treatment (Syfovre) can better slow the progression of geographic atrophy, a late-stage form of age-related macular degeneration that causes permanent vision loss. About 240 participant…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
One-Shot eye injection aims to halt blinding disease
Disease control Recruiting nowThis study is testing a new, one-time injection called CTx001 for people with geographic atrophy, a severe form of age-related macular degeneration that causes permanent vision loss. The main goals are to see if the injection is safe and if it can slow down the damage to the reti…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: Complement Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Zapping eyes with tiny currents to fight vision loss
Disease control Recruiting nowThis study is testing whether a gentle electrical current applied near the eye can help slow vision loss from dry age-related macular degeneration (AMD). About 100 participants with intermediate to advanced dry AMD will use the device at home for 11 months, with some receiving a …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: i-Lumen Scientific AUS PTY LTD • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New eye injection trial aims to slow blinding disease
Disease control Recruiting nowThis study is testing different doses of an investigational eye injection called FWY003 to see if it can slow the progression of geographic atrophy, a late-stage form of age-related macular degeneration that causes permanent vision loss. About 272 participants aged 50+ with this …
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Scientists track eye disease progression in real time
Knowledge-focused Recruiting nowThis observational study aims to better understand how geographic atrophy, a form of advanced age-related macular degeneration, progresses over a short period. Researchers will follow 75 participants aged 55 and older who have this condition in both eyes, using eye scans and visi…
Matched conditions: GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Sponsor: Complement Therapeutics • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC